We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Iofina Plc | IOF | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.25 | -1.22% | 20.25 | 10:48:58 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 20.50 | 20.25 | 20.50 | 20.25 | 20.50 |
| Industry Sector |
|---|
| CHEMICALS |
| Top Posts |
|---|
Posted at 22/4/2024 16:03 by j4ckster Seems like ramping to me. All the new posters have recently been active on the KEFI board, a "Gold" and copper exploration company. Can anyone think who else is linked to gold and iofina??? LOL. Lance trying to keep the price up here whilst his mates sell their IOF share to fund the new gold mine venture. Just a thought.🤔 |
Posted at 22/4/2024 11:44 by fft All very well making the connections, but IOF can already use or sell all the iodine they produce. IO10 will increase output, but given what seems to always be a gradual decline in output from any given plant over the years, all it is doing is keeping the numbers up. To make real use of potential like Germany, IOF would need a dash for growth. But does anyone see Tom doing that :-)BTW, whatever happened to the investment that was laid out on a product for a fortune 500 company. Did anyone ever hear of it again, or was it just another sop to shareholders to keep them quiet for another year (this was 5 years ago or so, but followed a trend if you read the interim and annual reports). |
Posted at 17/4/2024 13:03 by gb904150 This one I think you mean?Stocko says FY23 results out next Tuesday 23rd April. Regarding the brine supply contracts - Tom explains that while that agreement was in the supplier's favour at the start of the contract, it was in IOF's favour towards the end of it. The new contract is at a new market rate that is obviously now more beneficial for the supplier and will cost IOF a bit of profit in the short term, but over the course of the contract will probably even out. Perhaps IOF recognise that one of the reasons brine supply has been poor is because this contract no longer works well for the supplier. They figure a win-win is agreeing to a new contract which offers a higher brine price (but lower margins to IOF) but will result in higher brine supply. As ever, they are very conservative in their forecasts, but FY 2023 results I think will give us a much fuller picture. I know this company is hated by many investors, but fwics they are making slow but steady progress.....and are cheaply rated as such. Now if only they could start paying a divi and show they are investor friendly.... |
Posted at 11/4/2024 15:09 by severnof9 I share the same outlook as Chillpill in respect of quarter 1 and overall trading.The price per Kg of Iodine is favourable and the latest company updates are pointing toward a positive future for iodine production in my view. I particularly like these extracts from the Q4 Corporate update hxxps://iofina.com/q "Demand for the Company’s crystalline iodine remained robust during the final quarter, whilst sales of iodine derivatives had mixed results. Regarding non-iodine products, sales of a key product mainly used in the semiconductor industry improved significantly in the second half of the year after a slower-than-anticipa "In terms of new products, Iofina Chemical will be adding to its iodine derivatives product range in H1 2024, including an existing product in the market for which there is strong demand. The Company also expects to increase sales of its crystalline iodine to customers in Europe in 2024 through existing and new relationships." I read somewhere this week that IOF iodine sales to Europe make up 1% of iodine sales by geography with the vast majority going to the US and Asia. If sales can be generated in Europe that should help with turnover from increased iodine production. I have steadily purchased shares this week using up my 2024 ISA allowance on this unexplained dip so hoping for good news to come. Chillpill I know you state you have taken a recent deep dive into IOf regarding delays in the roll out of sites and I also note the reference to IO9 not being reliant of SWD due to its design. Any insight you can share on these comments would be appreciated. Many thnaks |
Posted at 10/4/2024 13:30 by beercapafn Lance is a risk and a confirmed risk.He should not be allowed to serve as a member of the BOD, more to the point, that he should be removed from having ANY influence on the ongoing influence in the future of IOF. He declared that he was fundraising for a new venture on the last visit to London and influenced at least one major long-term investor in IOR to sell up and move into his new venture. That is not the integrity and vision I seek in influencing IOF in any way. Please, Please, let's see his resignation, now - next RNS. Only with Lance out of the picture will IOF have the chance of Institutional investment and a new, more modern and dynamic strategic influence. We have better IP and cash generation than anyone else in this section of chemicals. So, just leaves management and shareholders return that needs addressing. Please. |
Posted at 16/2/2024 16:47 by jpegman "It doesn't matter where you are coming from. All that matters is where you are going" To that end -P/E 6.65 P/B 1.50 P/S 1.30 EV/EBITDA 4.70 Peer P/E 17.20 Industry P/E 13.00 Fair P/E 11.90 Fair Value (Share Price) £0.45 Earnings Growth Rate (5-Yr. Tr.) 66.90% EPS Growth Rate (5-Yr. Tr.) 69.30% Industry Earnings Outpeprformance (1 Yr. Tr.) 43.20% Increasing Net Profit Margins? Yes Industry Earnings Growth (5-Yr. Tr.) 4.30% Revenue Growth Rate (5-Yr. Tr.) 13.80% ROE 22.80% Net Margin 20.10% Stable Cash from Ops Growth? Yes Cash from Ops (£M) £9.49 Industry ROE 9.10% ROA 16.80% Industry ROA 7.10% ROCE (Last Year) 25.30% ROCE (3 years ago) 17.10% Debt/Equity (D/E) Ratio 14.60% Total Debt £4,780,000.00 Interest Coverage Ratio 116.5 Cash (£M) £4.98 Short Term Assets (£M) £23.25 Short Term Liabilities (£M) £8.37 Long Term Assets (£M) £21.74 Long Term Liabilities (£M) £3.85 Accellerating D/E Trajectory? Yes Dividend Yield 0.00% Div. Payout Ratio 0.00% Industry Avg. Yield 2.90% Shares Outstanding 192,237,623.76 Book Value (£M) £32.77 Percentage Marketable 67.51% Earnings Yield Above Risk-Free Rate 10.04% Price Margin of Safety 78.88% PE Margin of Safety 78.88% Price to Free Cash Flow 5.11 EBITDA (£M) £10.33 Debt-Adjusted ROE 19.47% Industry Earnings Outperformance (5Yr. Trailing) 62.60% Gearing Bonus 2.67% ROE Outperformance: 13.70% Buyback indicator 3.59% ROA Outperformance 9.70% ROCE Accelleration (ROCE - ROCE 3 Years ago) 8.20% Quick Ratio (Cash to Short term L) 0.59 Current Ratio (Short term A/L) 2.78 Long Term A/L 5.65 Excess Dividend -2.90% Proven upside from 12-Month High: +50.5% I estimate the following: Growth Multiplier 12.29% Prior CAGR 16.01% Value Score (MOS) 78.88% Earnings Accelleration 9.86 Risk Score 3 Implied PEG 0.37 Risk-Adjusted Fair Value Estimate £0.44 Price at 1x PEG £0.68 %MOS Currently Offered 74% Aside from some evidence of deceleration, These are highly attractive financials, just needs to be confirmed with a real-world business case. Currently, that is less obvious; I note that 1) Iofina has a unique competitive stance thanks to its vertical integration, and 2)being UK listed, investors benefit from the US business landscape without having to pay the US equities premium. |
Posted at 06/2/2024 15:30 by lostsole New LinkedIn post for IOF:https://www.link |
Posted at 31/1/2024 14:39 by lostsole LinkedIn post from IOFhttps://www.linke |
Posted at 09/6/2023 09:49 by beercapafn I asked Google - BARD Ai search engine what it knew about Iofina's share price.This was the response. An interesting positive report. View other drafts Iofina (IOF) is a specialty chemicals company that has seen its share price rise by 65% since January 4th, 2023. The company's stock has been on the rise due to strong demand for its products, which are used in a variety of industries, including water treatment, agriculture, and mining. In addition, Iofina has been expanding its operations into new markets, which has helped to boost its revenue and earnings. The company has also been investing in research and development, which has helped it to develop new products and improve its existing products. As a result of these factors, Iofina is well-positioned for continued growth in the future. The company's stock is currently trading at a P/E ratio of 10.38, which is below the average P/E ratio for the LSE. This makes Iofina a relatively undervalued stock, which could make it a good investment for investors who are looking for growth potential. However, it is important to note that there are some risks associated with investing in Iofina. The company is exposed to the cyclical nature of the chemicals industry, which could impact its revenue and earnings. Additionally, Iofina is a relatively small company, which could make it more susceptible to changes in the market. Overall, Iofina is a good company with a bright future. However, investors should be aware of the risks associated with investing in the company before making any investment decisions. Here are some of the reasons why Iofina's share price has risen so much since January 4th, 2023: Strong demand for its products Expansion into new markets Investment in research and development Relatively undervalued stock However, there are also some risks associated with investing in Iofina, such as: Cyclical nature of the chemicals industry Small company size Overall, Iofina is a good company with a bright future. However, investors should be aware of the risks associated with investing in the company before making any investment decisions. |
Posted at 12/1/2023 23:13 by dk37 A good review with some further comment on the Cannacord reportIofina [LON:IOF], the Colorado-headquarter As previously reported, Iofina currently operates five iodide extraction plants in the oilfields of Oklahoma and announced in 4Q22 the construction of a sixth plant in Western Oklahoma, IO#9. The company said that it has assembled the necessary materials and staff and started construction on IO#9, which it hopes to complete in 2Q23. Speedy payback As reported, Iofina secured debt financing in July 2022 to support the construction of the new extraction plant and the plant will come into immediate operation, contributing to revenues from the point of commissioning and would be in a position of full payback within two years. The company was targeting between 100 tonnes (T) and 150T of crystalline iodide production from the new site a year. Frontier Developments shares tumble as results disappoint This online gaming stock looks like a long term buy Premier African Minerals confident of lithium production this quarter Tom Becker, Iofina’s chief executive had previously told The Armchair Trader: “We could develop three or four more plants on this site in the next three-to-five years,” he said. New supply lines Becker said in a statement to the market that the company was sourcing additional brine supplies from oil and gas operators in the region with a view to building another extraction plant, IO#10 later this year. Becker said: “Negotiations continue to progress positively in line with Iofina’s commitment to achieve further expansion of iodine production capacity in the short term.” As previously reported, Iofina was targeting 255T to 275T production for 2H22. The company exceeded this target by producing 282T of crystalline iodide in the period, with total production for 2022 being 516T. Iofina has also been helped by an uptick in the global iodine prices increasing from USD50/Kg at the start of 2022 to USD70/Kg where it stabilised for most of the rest of the year. The company said that it expects prices to stay around the USD70/kg level for at least the first part of2023 as a result of tight global supply. Becker said that the company is aiming to produce between 235T and 250T of iodide in the first half of 2023, but noted that historically 1H production has always been lower than 2H production due to low temperatures in the winter months. Iofina opened trading today at 22.75p and has offered a year-to-date return of 12.2%, a one-year return of 15% with the company’s shares ranging between 13.53p and 28.5p over a 52-week period. The company has a market capitalization of GBP39.8m LSE:IOF quotes by TradingView Trade IOF on Hargreaves Lansdown or IG Iofina is the second-largest iodine producer in the US. A large amount of the world’s iodine comes from Chile, where bedrock in the Atacama Desert is blasted, crushed and leached in evaporation ponds, which is quite an intrusive, destructive and polluting process. Iofina, on the other hand chemically-extracts iodide from the brines rejected by the O&G producers, and then reinjects the wastewater back into the earth into empty oil wells. Increased global demand The largest current single use for iodine currently is in X-rays and medical imaging, where iodine targets soft tissue areas in the body, allowing medics to analyse damage or injury in these areas through biomedical imaging. This is leading to an increased global demand, especially as Asia upgrades its healthcare infrastructure. It is also used as a disinfectant and as a health supplement. Becker said the tech industry is experimenting with iodine in the manufacture of batteries for renewable energy projects and electric vehicles. Iodine is found in seawater and was traditionally extracted from seaweed, but it is also found in the remnants of prehistoric seas, as briny deposits sitting above layers of hydrocarbon-rich deposits, and in bedrock. Currently global production of iodine is 36,000T to 37,000T. Broker Canaccord Genuity recently published a research note on Iofina. Canaccord said: “Demand for the group’s products remain strong and the benchmark iodine price closed the year still at USD70/kg […] we have made minor changes to our 2022E numbers reflecting the higher production levels and we continue to see our forecasts as conservative. In particular, we are assuming an average iodine price for 2022E of USD55/kg (against a spot of USD70/kg) and production volume up just 7%.” The broker continued: “[This] could be entirely delivered just by the additional contribution on IO#9. […] we believe the group’s successful transition to not only being free cash flow positive, but with an exceptionally robust balance sheet has been underrated by the market.” Canaccord rate Iofina as a ‘Buy’ with a target price of 35p trading at a multiple of 13x to 15x and “increasing confidence for the outlook for the current year.” Deshe rate Iofina as a ‘Buy’ stating: “Iofina plc released impressive 2Q22 results on 26th September 2022. Specifically, their growth, value, and income factors indicate a well-planned and balanced effort, which is generating exciting growth. These results lead us to believe that there should be significant upside potential for the stock. Therefore, they earned a total score of 85 out of 100 and a ‘Buy’ recommendation.̶ |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
